These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 15788669)

  • 1. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
    Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
    Harpole DH; Moore MB; Herndon JE; Aloia T; D'Amico TA; Sporn T; Parr A; Linoila I; Allegra C
    Clin Cancer Res; 2001 Mar; 7(3):562-9. PubMed ID: 11297249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
    Hironaka S; Hasebe T; Kamijo T; Ohtsu A; Boku N; Yoshida S; Saitoh H; Ochiai A
    Clin Cancer Res; 2002 Jan; 8(1):124-30. PubMed ID: 11801548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
    Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
    Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
    Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
    Kim MK; Cho KJ; Kwon GY; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Kim SB
    Eur J Cancer; 2008 Jan; 44(1):54-60. PubMed ID: 17976974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
    Kajiwara T; Nishina T; Hyodo I; Moriwaki T; Endo S; Nasu J; Hori S; Matsuura B; Hiasa Y; Onji M
    Oncology; 2009; 76(5):342-9. PubMed ID: 19307741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma.
    Wang Y; Chen J; Li X; He Y; Hu B; Ji C; Xu J
    Oncol Rep; 2011 Apr; 25(4):1047-52. PubMed ID: 21286668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
    Langer R; Specht K; Becker K; Ewald P; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Verh Dtsch Ges Pathol; 2004; 88():207-13. PubMed ID: 16892554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
    Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
    Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
    J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.